The FDA has an ongoing Class II recall on dorzolamide hydrochloride and timolol maleate ophthalmic solution 2%/0.5%, 10 mL, manufactured by Micro Labs Limited in India and distributed by Micro Labs USA. The stated reason is a defective container: repeated complaints of broken cap spikes and undeliverable drops.
This is a delivery-device failure rather than a contamination or potency problem, which changes what it means clinically. The medicine in the bottle is not implicated. The risk is that a glaucoma patient believes they are instilling a drop twice a day and is not, and a fixed-combination product means both agents are missed together.
That failure mode is close to invisible in clinic. A patient with rising pressures on a stable regimen is usually investigated for adherence, progression or technique. A bottle that will not release a drop looks exactly like poor adherence and will be recorded as such unless someone asks to see the bottle.
The Indian relevance is direct: this is an Indian-manufactured product, and Micro Labs supplies the domestic market as well. Class II means a temporary or medically reversible consequence, which is the right classification for missed pressure control over weeks — but sustained uncontrolled pressure in advanced glaucoma is not reversible, and that is the patient to check first.
- In a glaucoma patient with unexplained pressure rise on dorzolamide-timolol, ask to see the bottle and watch them use it.
- Check the manufacturer on the pack: this recall names Micro Labs product specifically.
- This is a container fault, not a drug fault — the failure looks identical to non-adherence.
- Prioritise patients with advanced field loss, where weeks of missed pressure control is not recoverable.
- Replace rather than counsel: no amount of technique advice fixes a broken cap spike.
The statistics, in plain English
There is no effect size here; a recall is a regulatory action, not a study. The one term worth knowing is the class. Class II means exposure may cause temporary or medically reversible harm, with serious harm unlikely — a middle tier, above a labelling error and below a life-threatening defect. That classification is about the population, not your patient: reversible on average is still permanent field loss in someone with advanced disease and weeks of uncontrolled pressure. Status ongoing means the recall has not been terminated, so affected stock may still be in circulation.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free